Bryant Furlow

Contributing Writer https://www.cancertherapyadvisor.com

Bryant Furlow is a contract medical journalist for the Haymarket Medical Network. He holds a bachelor of science in biology (summa cum laude) from the University of New Mexico. He covers radiation oncology, immunotherapy, tumor biology, clinical research, and health care policy. Prior to becoming a contributor to Haymarket Media in 2010, Bryant was a newspaper reporter in New Mexico, where he won awards for public health and investigative journalism. He also reports for The Lancet Oncology news desk.

All articles by Bryant Furlow

The FDA’s accelerated approval of the PARP inhibitor rucaparib brings clinical prostate oncology into the precision medicine era.

Prostate Cancer

With Rucaparib Approval, Prostate Cancer Joins the Precision Oncology Era

Bryant Furlow

September 22, 2020

The FDA’s accelerated approval of the PARP inhibitor rucaparib brings clinical prostate oncology into the precision medicine era.

General Oncology

Stereotactic Body Radiotherapy: Past and Future Challenges

Bryant Furlow

September 10, 2020

Dr Sue Yom discusses the evolution and future of stereotactic body radiotherapy.

Patient receiving radiation therapy for cancer treatment in linear acelerator

Gynecologic Cancer

Radiotherapy for Cervical Cancer: An Introduction to ASTRO’s Clinical Practice Guideline

Bryant Furlow

July 14, 2020

The consensus guideline, drafted by an ASTRO-convened expert task force, offers recommendations about radiotherapy, including brachytherapy, and chemoradiation, in different stage-of-disease and treatment-strategy settings.

General Oncology

Few mHealth Apps Are Specific to Radiotherapy, But Helpful Tools Are Available

Bryant Furlow

April 15, 2020

A decade since the first wave of mobile device health apps hit the market there remain few designed specifically for patients who are undergoing radiation therapy for cancer. This review offers some useful tools available for patient education, organization, and coping.

Peripheral blood sample MRD assessment will likely come into routine clinical use in the next few years, according to an expert who specializes in CLL.

Chronic Lymphocytic Leukemia

Peripheral Blood MRD Shows Promise for Assessing CLL in Patients Treated With Venetoclax

Bryant Furlow

February 28, 2020

Peripheral blood sample MRD assessment will likely come into routine clinical use in the next few years, according to an expert who specializes in CLL.

A nationwide outbreak of EVALI reports has highlighted the unknowns about one of the most popular forms of inhalation drug use in the US.

Lung Cancer

Patients With Cancer Who Vape Are at Significant Risk for EVALI

Bryant Furlow

February 4, 2020

A nationwide outbreak of EVALI reports has highlighted the unknowns about one of the most popular forms of inhalation drug use in the US.

Renal Cell Carcinoma

Getting More Specific About Adjuvant Therapy Effects in Kidney Cancer

Bryant Furlow

December 27, 2019

Results from the phase 3 S-TRAC clinical trial suggested that for selected young and otherwise healthy patients, toxicities of sunitinib are manageable.

ASH 2019

Tirabrutinib Shows Promise in Waldenström Macroglobulinemia

Bryant Furlow

December 11, 2019

The second-generation Bruton tyrosine kinase inhibitor tirabrutinib (ONO/GS-4059) showed promising efficacy in patients with treatment-naive (TN) or relapsed/refractory (RR) Waldenström macroglobulinemia (WM).

Biomarker detects early-stage lung cancer.

ASH 2019

Inotuzumab Ozogamicin Shows Clinical Efficacy in Relapsed Pediatric B-ALL

Bryant Furlow

December 11, 2019

Inotuzumab ozogamicin (InO) exhibits clinical efficacy against heavily pretreated, relapsed CD22-positive pediatric B-cell acute lymphoblastic leukemia (B-ALL).

ASH 2019

Epigenetic Drug CPI-0610 Called Clinically Active, Tolerable in Myelofibrosis

Bryant Furlow

December 9, 2019

“Among evaluable patients who were transfusion dependent on ruxolitinib, 6 of 14 patients converted to transfusion independence after the addition of CPI-0610.”

Next post in ASH 2019